Noorderhart

The Neurology department at Noorderhart concentrates on Multiple Sclerosis, a disease rooted in abnormal immune system responses. Current trials evaluate novel immunotherapies such as ocrelizumab and remibrutinib to lower relapse frequency and delay disability. Researchers also investigate biomarkers, including neurofilament, to better track disease activity and treatment impact.

• High‑dose ocrelizumab compared with standard dosing for relapsing disease
• BTK inhibitor studies targeting primary progressive forms
• Serum neurofilament level monitoring as a surrogate endpoint
• Head‑to‑head efficacy comparisons of new oral agents versus established therapies
• Switch studies assessing outcomes after transitioning from ocrelizumab to alternative treatments

The site engages a multidisciplinary team to ensure participants receive comprehensive care while contributing valuable data that may shape future therapeutic strategies.

In the realm of nervous system diseases, Noorderhart’s research emphasizes both relapsing‑remitting and progressive Multiple Sclerosis phenotypes. Trials aim to improve diagnostic imaging using advanced magnetic resonance imaging techniques and to assess interventions that mitigate disability progression. The overarching goal is to refine clinical outcomes and enhance quality of life for patients living with this chronic neurological condition.

• Comparison of subcutaneous versus intravenous administration routes for emerging antibodies
• Long‑term safety and efficacy follow‑up across diverse MS subtypes
• MRI lesion count reduction as a primary efficacy measure
• Investigations into non‑relapsing secondary progressive MS
• Pharmacokinetic similarity studies of biosimilar agents versus reference biologics

By integrating patient‑reported outcomes with rigorous scientific assessment, the center strives to advance therapeutic options and support informed decision‑making for those affected by neurological disorders.